Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 17/20 | 0.78 |
| ▸ | INSR | P06213 | 7/20 | 0.78 |
| ▸ | IGF1R | P08069 | 6/20 | 0.78 |
| ▸ | EGFR | P00533 | 3/20 | 0.78 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.78 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.78 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.78 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.78 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.78 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.78 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.78 |
| ▸ | PLK4 | O00444 | 2/20 | 0.78 |
| ▸ | GAK | O14976 | 2/20 | 0.78 |
| ▸ | ERN1 | O75460 | 2/20 | 0.78 |
| ▸ | STK10 | O94804 | 2/20 | 0.78 |
| ▸ | ABL1 | P00519 | 2/20 | 0.78 |
| ▸ | LCK | P06239 | 2/20 | 0.78 |
| ▸ | FYN | P06241 | 2/20 | 0.78 |
| ▸ | FES | P07332 | 2/20 | 0.78 |
| ▸ | YES1 | P07947 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12892763 | 0.99 | ALK (0.77) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL12781735 | 0.94 | ALK (0.88) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL12780141 | 0.94 | ALK (0.88) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL1912035 | 0.93 | ALK (0.76) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL14981305 | 0.93 | ALK (0.74) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL12780112 | 0.92 | ALK (0.88) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL12892759 | 0.92 | ZAP70 (0.69) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL12780642 | 0.91 | ALK (0.73) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL12780264 | 0.90 | ALK (0.78) | ALKINSRIGF1REGFRPTK2 | |
| SCHEMBL12892761 | 0.90 | EGFR (0.68) | ALKINSRIGF1REGFRPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
| US-7893074-B2 | inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide | NOVARTIS AG (CH) | 2011-02-22 | — | — | US | disclosed |
| US-7893074-B2 | inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide | NOVARTIS AG (CH) | 2011-02-22 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | TYMS, TYMP, DPYD | ALK 3384/4885INSR 3201/4885IGF1R 4627/4885 |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | TYMS, TYMP, DPYD | ALK 3200/4885INSR 2899/4885IGF1R 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.